JP2020517658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517658A5 JP2020517658A5 JP2019557434A JP2019557434A JP2020517658A5 JP 2020517658 A5 JP2020517658 A5 JP 2020517658A5 JP 2019557434 A JP2019557434 A JP 2019557434A JP 2019557434 A JP2019557434 A JP 2019557434A JP 2020517658 A5 JP2020517658 A5 JP 2020517658A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- antibody
- cancer
- ecm
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001630A JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487823P | 2017-04-20 | 2017-04-20 | |
| US62/487,823 | 2017-04-20 | ||
| PCT/US2018/028505 WO2018195386A1 (en) | 2017-04-20 | 2018-04-20 | Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001630A Division JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517658A JP2020517658A (ja) | 2020-06-18 |
| JP2020517658A5 true JP2020517658A5 (enExample) | 2021-05-27 |
| JP7419070B2 JP7419070B2 (ja) | 2024-01-22 |
Family
ID=63856403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557434A Active JP7419070B2 (ja) | 2017-04-20 | 2018-04-20 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
| JP2024001630A Pending JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001630A Pending JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11574747B2 (enExample) |
| EP (1) | EP3612209A4 (enExample) |
| JP (2) | JP7419070B2 (enExample) |
| CN (1) | CN111132693A (enExample) |
| AU (2) | AU2018256453B2 (enExample) |
| MX (1) | MX2019012579A (enExample) |
| WO (1) | WO2018195386A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2911669B1 (en) * | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| EP3612209A4 (en) * | 2017-04-20 | 2021-03-24 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH MEC AFFINITY PEPTIDES RELATED TO IMMUNOTHERAPEUTIC ANTIBODIES |
| US11732029B2 (en) | 2017-11-13 | 2023-08-22 | The University Chicago | Methods and compositions for the treatment of wounds |
| WO2019173289A1 (en) | 2018-03-05 | 2019-09-12 | The University Of Chicago | Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines |
| AU2019299110B2 (en) * | 2018-07-03 | 2025-07-17 | Catalent Pharma Solutions, Llc | Multifunctional protein molecules comprising decorin and use thereof |
| WO2020176478A1 (en) * | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| CA3144533A1 (en) * | 2019-06-03 | 2020-12-10 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
| WO2021127254A1 (en) * | 2019-12-19 | 2021-06-24 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| CN115065734A (zh) * | 2021-02-27 | 2022-09-16 | 华为技术有限公司 | 一种数据处理方法、装置及芯片 |
| WO2025203029A1 (en) * | 2024-03-28 | 2025-10-02 | Hadasit Medical Research Services And Development Ltd. | Tricer - a tri-specific cell engager and retainer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
| WO2001016180A2 (en) * | 1999-08-27 | 2001-03-08 | Board Of Regents, The University Of Texas System | Cd40 agonist compositions and methods of use |
| WO2001085192A1 (en) | 2000-05-05 | 2001-11-15 | Gtc Biotherapeutics, Inc. | Transgenically produced decorin |
| US20080160024A1 (en) * | 2006-12-07 | 2008-07-03 | Board Of Trustees Of The University Of Arkansas | Inhibition of cancer metastasis |
| AT504685B1 (de) | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| HUE029454T2 (en) * | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| US9879062B2 (en) | 2012-07-03 | 2018-01-30 | Ecole Polytechnique Federale De Lausanne | Protein-binding peptide isolated from placenta growth factor |
| WO2016054107A1 (en) | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| EP3612209A4 (en) * | 2017-04-20 | 2021-03-24 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH MEC AFFINITY PEPTIDES RELATED TO IMMUNOTHERAPEUTIC ANTIBODIES |
-
2018
- 2018-04-20 EP EP18787963.0A patent/EP3612209A4/en active Pending
- 2018-04-20 WO PCT/US2018/028505 patent/WO2018195386A1/en not_active Ceased
- 2018-04-20 JP JP2019557434A patent/JP7419070B2/ja active Active
- 2018-04-20 CN CN201880041832.4A patent/CN111132693A/zh active Pending
- 2018-04-20 AU AU2018256453A patent/AU2018256453B2/en active Active
- 2018-04-20 MX MX2019012579A patent/MX2019012579A/es unknown
- 2018-04-20 US US16/606,539 patent/US11574747B2/en active Active
-
2023
- 2023-02-03 US US18/164,164 patent/US20230377764A1/en active Pending
-
2024
- 2024-01-10 JP JP2024001630A patent/JP2024041874A/ja active Pending
- 2024-05-02 AU AU2024202918A patent/AU2024202918A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517658A5 (enExample) | ||
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Balza et al. | Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin | |
| Fallon et al. | The immunocytokine NHS-IL12 as a potential cancer therapeutic | |
| JP6858558B2 (ja) | 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬 | |
| JP2023524530A (ja) | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 | |
| JP2021020909A (ja) | がんの治療のための方法、組成物、及びキット | |
| WO2017023749A1 (en) | Compositions and methods for immunomodulation | |
| JP2016527286A5 (enExample) | ||
| JP2019526578A (ja) | キャリアー−ｐｄ−ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 | |
| US20220008515A1 (en) | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor | |
| JP7139293B2 (ja) | Ｇｄ２陽性がんを処置するための製剤および方法 | |
| JP2021120418A (ja) | がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム | |
| CN103536917B (zh) | 干扰素在治疗肿瘤中的用途及相关的产品和方法 | |
| WO2021068196A1 (en) | Methods of using il-33 protein in treating cancers | |
| Dianat-Moghadam et al. | Immunotherapies targeting tumor vasculature: challenges and opportunities | |
| US20220249621A1 (en) | TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS | |
| JP2020528449A5 (enExample) | ||
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| US20240216554A1 (en) | Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer | |
| TWI812820B (zh) | 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法 | |
| CN107001484A (zh) | 使用肽‑蛋白质轭合物治疗肿瘤 | |
| US11419894B2 (en) | Modified natural killer cells for the treatment of cancer | |
| JPWO2019173289A5 (enExample) |